Tools and Technology Update

FDA clears low-dose X-ray imager
Biospace med announced that it has received 510k clearance from the Food and Drug Administration (FDA) to market EOS, a new, digital X-ray imager in the United States for 2D imaging use. According to the company’s press release, the technology enables images to be obtained with a low dose of radiation and is capable of long-length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan.

The company claims that EOS differs in several other respects from traditional film, digital X-ray, or computed tomography, pointing to its use of slot scanning technology to eliminate vertical distortion and its ability to acquire front and side images simultaneously.

Biospace med believes the low-dose benefits of EOS may be particularly useful for patients with spinal disorders, such as scoliosis, who must typically undergo numerous radiographic exams to monitor progression of the disease as well as treatment effectiveness. The company has corporate headquarters in Paris and Atlanta with an office in Montreal. Learn more at www.biospacemed.com

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement